Literature DB >> 17519648

Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration.

Babur Yusufi1, Sujoy Mukherjee, Robert Flanagan, Carol Paton, Graham Dunn, Eleanor Page, Thomas R E Barnes.   

Abstract

Clozapine is associated with non-neurological side effects that can be subjectively unpleasant and/or clinically serious. We sought to: (i) assess the nature and prevalence of side effects experienced by patients receiving maintenance treatment with clozapine and (ii) explore the relationship between clozapine plasma concentration and side effect burden. Patients were receiving clozapine maintenance treatment. Open questioning followed by systematic enquiry using the Antipsychotic Non-neurological Side Effects Rating Scale were used to assess side effects. Trough plasma clozapine and norclozapine concentrations were measured. One hundred and three patients participated. On open questioning, 61 patients reported a total of 117 side effects, whereas systematic enquiry identified an additional 649 side effects, with each patient reporting at least one. Clozapine plasma concentrations were significantly but weakly correlated with total Antipsychotic Non-neurological Side Effects Rating Scale score (Pearson correlation=0.29, P<0.004). Patients with a plasma clozapine concentration >0.25 mg/l were significantly more likely to have moderate/severe side effects than patients with lower plasma concentrations (63/76 vs. 12/23, chi=9.07, d.f.=1, P<0.01). The side-effect burden associated with maintenance clozapine treatment is high and the true extent can only be ascertained by systematic inquiry. The use of target plasma concentrations below those used for acute treatment should be explored as a strategy for minimizing side effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17519648     DOI: 10.1097/YIC.0b013e32819f8f17

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  21 in total

1.  Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life.

Authors:  Senan Maher; Aoife Cunningham; Niamh O'Callaghan; Fintan Byrne; Colm Mc Donald; Shane McInerney; Brian Hallahan
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-30

Review 2.  A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.

Authors:  Madeleine S A Tan; Faraz Honarparvar; James R Falconer; Harendra S Parekh; Preeti Pandey; Dan J Siskind
Journal:  Psychopharmacology (Berl)       Date:  2021-01-07       Impact factor: 4.530

3.  Botulinum toxin: a novel therapy for clozapine-induced sialorrhoea.

Authors:  Rohit Verma; Kuljeet Singh Anand
Journal:  Psychopharmacology (Berl)       Date:  2017-12-01       Impact factor: 4.530

Review 4.  Clozapine and Gastrointestinal Hypomotility.

Authors:  Dan Cohen
Journal:  CNS Drugs       Date:  2017-12       Impact factor: 5.749

Review 5.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

6.  The ANNSERS (Antipsychotic Non-Neurological Side Effects Rating Scale): Validation of Sexual Side-Effect Measurement.

Authors:  Ahmed Mahmoud; Karen P Hayhurst; Richard J Drake; Shôn W Lewis; Thomas R E Barnes
Journal:  Ther Adv Psychopharmacol       Date:  2011-08

Review 7.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

8.  Development of the My Medicines and Me (M3Q) side effect questionnaire for mental health patients: a qualitative study.

Authors:  Deena M Ashoorian; Rowan M Davidson; Daniel J T Rock; Liza J Seubert; Rhonda M Clifford
Journal:  Ther Adv Psychopharmacol       Date:  2015-10

9.  Factors predicting use of laxatives in outpatients stabilized on clozapine.

Authors:  Loren Bailey; Seema Varma; Nina Ahmad; Siobhan Gee; David M Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2015-10

10.  Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study.

Authors:  Nobuyuki Nomura; Kohei Kitagawa; Ryuhei So; Fuminari Misawa; Masafumi Kodama; Hiroyoshi Takeuchi; Robert Bies; Thomas Straubinger; Christopher Banker; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Ther Adv Psychopharmacol       Date:  2021-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.